Zacks Research Has Negative View of Bruker FY2024 Earnings

Bruker Co. (NASDAQ:BRKR - Free Report) - Analysts at Zacks Research decreased their FY2024 earnings per share estimates for shares of Bruker in a report issued on Tuesday, November 26th. Zacks Research analyst R. Department now expects that the medical research company will post earnings of $2.40 per share for the year, down from their prior forecast of $2.60. The consensus estimate for Bruker's current full-year earnings is $2.40 per share. Zacks Research also issued estimates for Bruker's Q4 2024 earnings at $0.75 EPS, Q1 2025 earnings at $0.51 EPS, Q2 2025 earnings at $0.59 EPS, FY2025 earnings at $2.78 EPS, Q1 2026 earnings at $0.86 EPS, Q2 2026 earnings at $0.84 EPS, Q3 2026 earnings at $0.82 EPS and FY2026 earnings at $3.42 EPS.

Bruker (NASDAQ:BRKR - Get Free Report) last announced its quarterly earnings results on Tuesday, November 5th. The medical research company reported $0.60 earnings per share for the quarter, missing the consensus estimate of $0.61 by ($0.01). Bruker had a return on equity of 21.52% and a net margin of 9.41%. The business had revenue of $864.40 million during the quarter, compared to the consensus estimate of $866.46 million. During the same quarter in the prior year, the firm posted $0.74 EPS. The company's revenue for the quarter was up 16.4% on a year-over-year basis.

Several other equities research analysts have also recently weighed in on the company. Wolfe Research cut Bruker from an "outperform" rating to a "peer perform" rating in a research note on Monday, September 30th. TD Cowen cut their target price on Bruker from $72.00 to $70.00 and set a "hold" rating on the stock in a research report on Wednesday, November 6th. Barclays lowered their price target on Bruker from $75.00 to $69.00 and set an "overweight" rating for the company in a research report on Wednesday, November 6th. Citigroup cut their price objective on shares of Bruker from $80.00 to $75.00 and set a "buy" rating on the stock in a research report on Wednesday, November 6th. Finally, Wells Fargo & Company lowered their target price on shares of Bruker from $78.00 to $75.00 and set an "overweight" rating for the company in a report on Wednesday, November 6th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat, Bruker presently has a consensus rating of "Moderate Buy" and an average target price of $79.36.

Bruker Price Performance

Shares of NASDAQ BRKR traded up $0.88 during mid-day trading on Wednesday, hitting $58.38. 1,436,451 shares of the company's stock traded hands, compared to its average volume of 1,115,677. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.66 and a quick ratio of 0.73. Bruker has a 1 year low of $48.07 and a 1 year high of $94.86. The company's 50-day moving average is $61.18 and its two-hundred day moving average is $64.29. The company has a market capitalization of $8.85 billion, a P/E ratio of 28.07, a PEG ratio of 3.95 and a beta of 1.20.

Bruker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 16th. Stockholders of record on Monday, December 2nd will be paid a dividend of $0.05 per share. The ex-dividend date of this dividend is Monday, December 2nd. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.34%. Bruker's dividend payout ratio is presently 9.62%.

Insider Activity at Bruker

In related news, CEO Frank H. Laukien acquired 100,000 shares of the company's stock in a transaction that occurred on Monday, November 18th. The shares were bought at an average price of $50.14 per share, with a total value of $5,014,000.00. Following the completion of the transaction, the chief executive officer now directly owns 38,439,563 shares in the company, valued at $1,927,359,688.82. This trade represents a 0.26 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 28.30% of the stock is currently owned by corporate insiders.

Institutional Trading of Bruker

Several hedge funds have recently modified their holdings of the company. Sanctuary Advisors LLC increased its position in shares of Bruker by 95.8% during the third quarter. Sanctuary Advisors LLC now owns 9,089 shares of the medical research company's stock worth $628,000 after purchasing an additional 4,447 shares in the last quarter. Coldstream Capital Management Inc. grew its stake in Bruker by 7.3% during the 3rd quarter. Coldstream Capital Management Inc. now owns 4,553 shares of the medical research company's stock worth $312,000 after buying an additional 308 shares during the last quarter. Geode Capital Management LLC increased its position in Bruker by 10.8% during the 3rd quarter. Geode Capital Management LLC now owns 1,993,468 shares of the medical research company's stock valued at $137,702,000 after buying an additional 193,580 shares in the last quarter. Barclays PLC raised its stake in Bruker by 36.5% in the third quarter. Barclays PLC now owns 55,685 shares of the medical research company's stock valued at $3,847,000 after buying an additional 14,888 shares during the last quarter. Finally, MML Investors Services LLC boosted its holdings in Bruker by 9.2% in the third quarter. MML Investors Services LLC now owns 31,820 shares of the medical research company's stock worth $2,198,000 after acquiring an additional 2,693 shares in the last quarter. 79.52% of the stock is owned by hedge funds and other institutional investors.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.